NCT04521140View on ClinicalTrials.gov

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

January 4, 2023

Study Completion Date

January 4, 2023

Conditions
Corneal EdemaCorneal DefectCorneal TransplantPenetrating KeratoPlastyAnterior Chamber InflammationOcular PainIntraocular Pressure
Interventions
DRUG

Dextenza 0.4Mg Ophthalmic Insert

DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

DRUG

Prednisolone Acetate 1% Oph Susp

Prednisolone Acetate 1% is a corticosteroid used as a topical drop after corneal transplant to decrease inflammation and prevent graft rejection

Trial Locations (1)

90067

Advanced Vision Care, Los Angeles

All Listed Sponsors
lead

Nicole Fram M.D.

OTHER

NCT04521140 - Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery | Biotech Hunter | Biotech Hunter